恶性黑色素瘤的免疫治疗进展

Progress in Immunotherapy of Malignant Melanoma

恶性黑色素瘤病死率高、预后差,但随着基础免疫学和肿瘤生物学的迅速发展,针对恶性黑色素瘤发生发展、侵袭转移的过程所进行的免疫治疗正进入一个新时期,黑色素瘤患者的生存获得可观改善。目前免疫治疗主要围绕PD-1单克隆抗体、CTLA-4单克隆抗体、免疫联合治疗展开。Pembrolizumab、Nivolumab、Ipilimumab单用、Nivolumab联合Ipilimumab以及Talimogene laherparepvec均已被证明是有效和安全的,已被美国食品药品管理局(FDA)批准用于恶性黑色素瘤的治疗。该文概述了目前免疫治疗药物的最新进展,并探讨其前景及挑战。

The high mortality and poor prognosis of malignant melanoma make it a serious threat to human health.With the rapid development of basic immunology and tumor biology,the immunotherapy of malignant melanoma is entering a new era,immunotherapy for the occurrence,development,invasion and metastasis of malignant melanoma is entering a new stage,and the survival of melanoma patients has been significantly improved.At present,immunotherapy mainly focuses on the combination of PD-1 monoclonal antibody,CTLA-4 monoclonal antibody and immunotherapy.Pembrolizumab,Nivolumab,Ipilimumab used alone,Nivolumab in combination with Ipilimumab and Talimogene laherparepvec have been proven to be effective and safe and have been approved by the FDA for the treatment of malignant melanoma.This article will review the latest advances in immunotherapy drugs and discuss their prospects and challenges.